Which Companies Lead the Peptide and Oligonucleotide CDMO Market in 2026?

Peptide and Oligonucleotide CDMO by Type (Peptide CDMO, Oligonucleotide CDMO), by Application (Pharmaceutical and Biotechnology Companies, Research Institutes, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Peptide and Oligonucleotide CDMO Market Overview

Market definition: The Peptide and Oligonucleotide CDMO market comprises contract development and manufacturing organizations that provide end‑to‑end services—from custom synthesis to scale‑up and formulation—for therapeutic peptides, antisense oligonucleotides, siRNA, and related modalities. Its relevance stems from the accelerating pipeline of biologics and gene‑editing therapies that demand specialized, high‑purity manufacturing capabilities.

Executive‑ready intro: The Peptide and Oligonucleotide CDMO market size reached approximately $4.2 billion in 2025, reflecting robust growth outlook driven by expanding biologics pipelines. Analysts project a market forecast through 2033 with an industry expansion trajectory that underscores the sector’s strategic importance for pharmaceutical outsourcing.

Loading chart…

From 2026 to 2033 the market is projected to expand at a CAGR of ~11%, propelled by macro drivers such as the surge in personalized medicine, mRNA‑based vaccines, and gene‑editing therapeutics that require rapid, GMP‑compliant scale‑up. Key forces shaping the landscape include (1) technological shifts toward automated flow chemistry and AI‑guided sequence design, (2) tightening regulatory frameworks that favor CDMOs with validated quality systems, and (3) intensifying competitive dynamics as biotech firms increasingly outsource to accelerate time‑to‑market.

Geographically, North America remains the largest market, anchored by the United States’ mature biotech ecosystem, while Asia‑Pacific is the fastest‑growing region, driven by expanding R&D investments in China, India, and Japan. These trends signal sustained demand for specialized CDMO capabilities and present strategic opportunities for service providers aiming to capture the next wave of biologics innovation.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lonza Group Ltd.; Thermo Fisher Scientific Inc.; Merck KGaA; Catalent, Inc.; Genscript Biotech Corporation; Polypeptide Group; Bachem Holding AG; Wuxi Apptec Co.,Ltd.; Ajinomoto Co.,Inc.; Rentschler Biopharma SE; Corden Pharma GmbH; Senn Chemicals AG; Almac Group; Lonza Custom Manufacturing; Creative Peptides; Swiss Customized Synthesis; Syngene; Eurogentec
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Peptide and Oligonucleotide CDMO market is at a pivotal inflection point, with evolving therapeutic paradigms and supply‑chain realignments reshaping its trajectory. This Market Dynamics section distills the principal forces that are influencing the Peptide and Oligonucleotide CDMO market size and the associated growth forecast for the coming decade.

Growth Drivers2 items

Accelerating demand for personalized therapeutics and mRNA vaccines is pushing biopharma firms to outsource peptide and oligonucleotide manufacturing, expanding the Peptide and Oligonucleotide CDMO market size and prompting a robust growth forecast through 2032.

Advances in solid‑phase synthesis automation and high‑throughput analytical platforms lower time‑to‑market, enabling CDMOs to offer end‑to‑end services that attract late‑stage pipeline candidates and increase contract volumes.

Restraints2 items

Stringent regulatory pathways for nucleic‑acid therapeutics, especially in emerging markets, extend approval timelines and raise compliance costs, tempering the pace of new CDMO engagements.

Concentrated supplier base for specialty raw materials such as protected nucleosides creates price volatility, squeezing margins for CDMOs and limiting their ability to scale capacity without passing costs to clients.

Opportunities2 items

Integration of continuous‑flow manufacturing with real‑time release testing opens a pathway for CDMOs to deliver on‑demand batch sizes, aligning with the shift toward decentralized clinical trial sites and creating a differentiated service tier.

Strategic partnerships with AI‑driven design firms enable CDMOs to co‑develop sequence‑optimized candidates, unlocking premium pricing models and expanding the addressable market beyond traditional small‑molecule analogues.

Challenges2 items

Talent scarcity in high‑skill chemists and process engineers capable of handling complex oligonucleotide chemistries forces CDMOs to compete for limited human capital, potentially delaying project ramp‑up.

Geopolitical trade restrictions on key export controls for peptide synthesis equipment and dual‑use chemicals increase lead times and compel CDMOs to diversify manufacturing footprints, adding operational complexity.

Market Segmentation

Loading chart…

Peptide CDMO segmentation can be parsed along two primary axes—type and application. Type distinguishes service models such as custom peptide synthesis, process development, and full‑scale contract manufacturing under GMP conditions. Custom synthesis captures early‑stage discovery projects, contributing modest revenue but driving pipeline volume; process‑development services bridge discovery and scale‑up, adding higher margin; GMP manufacturing represents the bulk of market size, delivering large‑batch production for commercial biologics. Application separates end‑uses into therapeutics, diagnostics, and research services. Therapeutic peptides, driven by oncology and metabolic indications, command the largest share of contract manufacturing capacity, directly inflating overall market valuation. Diagnostic peptides, used in assay kits and imaging agents, occupy a niche but benefit from higher per‑unit pricing. Research‑grade peptides sustain a steady demand for small‑scale batches, supporting academic and biotech R&D. Collectively, these sub‑segments define the “Peptide and Oligonucleotide CDMO segmentation” landscape, where type‑driven value‑addition and application‑driven volume together shape total market size.

Oligonucleotide CDMO segmentation follows a comparable taxonomy, with type and application as the decisive dimensions. Type differentiates service tiers: custom oligonucleotide synthesis (including ASO, siRNA, miRNA, and emerging mRNA), analytical development, and large‑scale GMP manufacturing. Custom synthesis supports early‑stage programs and accounts for a high‑mix, low‑volume revenue stream; analytical development adds value through purity testing and stability studies; GMP manufacturing, particularly for ASO and siRNA, drives the majority of market revenue due to multi‑kilogram production for approved drugs. Application categories—therapeutics, diagnostics, and research—allocate demand across clinical and non‑clinical uses. Therapeutic oligonucleotides dominate the CDMO pipeline, reflecting accelerated regulatory approvals in rare diseases and oncology; diagnostic oligos, employed in liquid‑biopsy and companion‑diagnostic assays, contribute a smaller but rapidly growing slice; research oligos sustain baseline activity across academic and biotech laboratories. This market taxonomy clarifies how type‑specific capabilities and application‑specific demand jointly determine the overall size of the oligonucleotide CDMO sector.

Peptide and Oligonucleotide CDMO Segmentation Breakdown7 items

Type

Peptide CDMO

Oligonucleotide CDMO

Application

Pharmaceutical and Biotechnology Companies

Research Institutes

Others

Regional Insights

Loading chart…

North America remains the largest market, accounting for roughly 35% of the global peptide and oligonucleotide CDMO market share. Asia Pacific is the fastest‑growing region, projected to outpace peers with a compound annual growth rate exceeding 12% through 2030, driven by expanding biotech hubs and supportive policy frameworks.

In North America, mature R&D ecosystems, robust venture capital pipelines, and FDA’s streamlined guidance for advanced therapeutics underpin market growth. Strategic investments by leading CDMOs in state‑of‑the‑art facilities further accelerate capacity expansion, while a skilled workforce sustains high‑value service delivery.

Europe’s growth is fueled by the European Union’s Horizon Europe funding, which earmarks billions for peptide and oligonucleotide innovation. Strong regulatory harmonization across member states and the rise of contract‑manufacturing clusters in Germany, the UK, and Switzerland enhance ecosystem maturity and attract multinational sponsors.

Asia Pacific benefits from government incentives such as China’s “Made in China 2025” and India’s biotech corridor initiatives, spurring domestic CDMO capacity. Rapidly expanding clinical trial networks, coupled with a growing pool of biotech talent, position the region as a hub for cost‑effective, high‑quality manufacturing.

Latin America’s market is emerging, driven by Brazil’s recent tax relief for biotech manufacturing and Mexico’s proximity to U.S. clinical sites. Investment in cold‑chain logistics and a burgeoning startup scene are laying the groundwork for future regional forecast optimism.

The Middle East & Africa region shows modest but steady growth, anchored by Saudi Arabia’s Vision 2030 investment in life‑science infrastructure and South Africa’s expanding research universities. Public‑private partnerships are beginning to create a viable CDMO ecosystem, supporting niche peptide and oligonucleotide projects.

Competitive Landscape

The Peptide and Oligonucleotide CDMO competitive landscape is moderately consolidated, with a handful of multinational firms accounting for a sizable share of capacity while a larger pool of regional players serves niche markets. Global contractors such as Lonza, Thermo Fisher and Merck leverage extensive GMP networks and broad technology portfolios to win large‑scale programs, whereas local firms compete on price, rapid turnaround and proximity to biotech clusters. Competitive levers centre on pricing elasticity, depth of regulatory certifications, breadth of synthesis chemistries, and ability to secure long‑term partnership agreements. Distribution channels remain service‑driven, with customers often selecting partners based on demonstrated compliance history rather than pure cost considerations. Consequently, firms with Tier‑1 FDA and EMA approvals can command modest price premiums.

Key strategies across the segment include targeted M&A to acquire specialized peptide synthesis capabilities, joint ventures that expand geographic reach, and the launch of integrated analytics platforms that shorten development cycles. Companies also invest in process‑intensification R&D to reduce cost per gram and differentiate through custom sequence design services. Customization depth also serves as a differentiator for early‑stage biotech customers seeking rapid prototyping. Several CDMOs pursue vertical integration, adding formulation and fill‑finish capacity to capture higher‑margin downstream work. Meanwhile, regulatory pressure and rising compliance costs compress margins, prompting firms to seek economies of scale or niche premium pricing. Supply‑chain volatility for critical raw materials further incentivizes partnerships with raw‑material suppliers and the development of in‑house inventory buffers.

Lonza Group Ltd. – vertical integration of peptide synthesis and fill‑finish services.

Thermo Fisher Scientific Inc. – expanding regional manufacturing hubs in Europe and Asia.

Merck KGaA – premium pricing for proprietary oligonucleotide chemistries.

Catalent, Inc. – OEM tie‑ups with large‑scale biotech firms.

Genscript Biotech Corporation – innovation pipeline focused on rapid custom peptide libraries.

Wuxi Apptec Co.,Ltd. – local manufacturing expansion to serve Chinese biotech clusters.

Key Peptide and Oligonucleotide CDMO Companies18 items

Lonza Group Ltd.

Thermo Fisher Scientific Inc.

Merck KGaA

Catalent, Inc.

Genscript Biotech Corporation

Polypeptide Group

Bachem Holding AG

Wuxi Apptec Co.,Ltd.

Ajinomoto Co.,Inc.

Rentschler Biopharma SE

Corden Pharma GmbH

Senn Chemicals AG

Almac Group

Lonza Custom Manufacturing

Creative Peptides

Swiss Customized Synthesis

Syngene

Eurogentec

Market Ecosystem

The Peptide and Oligonucleotide CDMO ecosystem covers a value chain from upstream raw‑material supply through midstream process development and GMP manufacturing to downstream logistics and distribution. Upstream suppliers provide amino acids, nucleotides, and protected building blocks. Midstream actors—technology vendors, equipment OEMs, and CDMOs—integrate synthesis platforms, purification modules, and analytical tools to produce clinical‑grade material. Downstream channels handle regulatory filing, cold‑chain logistics, and delivery to pharmaceutical and biotech end users. Value accrues mainly at the CDMO stage via service fees, while upstream and downstream partners earn margins on inputs and delivery.

Raw material/component suppliers — provide amino acids, nucleotides, and protected monomers for synthesis.

Technology providers — supply automation software, monitoring systems, and analytical instruments for process control.

CDMOs (development & manufacturing) — conduct sequence design, scale‑up, GMP production, and quality release.

System integrators / EPCs — design and commission dedicated peptide/oligonucleotide facilities with utilities and containment.

Distributors / channel partners — manage cold‑chain logistics, customs clearance, and inventory buffering for end‑user delivery.

Regulators / standards bodies — set GMP, impurity, and labeling requirements governing validation and release.

Financing / leasing partners — offer equipment leasing and project financing to reduce CDMO CAPEX.

Within the Peptide and Oligonucleotide CDMO ecosystem, regulatory compliance and technology compatibility constitute the primary control points; any change in GMP standards or analytical method acceptance directly influences CDMO capacity utilization. Dependency risks arise from limited sources of high‑purity nucleotides and from the need for validated equipment, creating potential bottlenecks in scale‑up. Switching between CDMOs incurs substantial process transfer costs and requires alignment of data formats and quality systems, reinforcing long‑term partnership structures. Regional variations in regulatory timelines and supplier concentration can further affect lead‑time and cost dynamics across North America, Europe, and APAC.

Recent Industry Insights

Over the past 12‑18 months the Peptide and Oligonucleotide CDMO industry trends have accelerated through strategic alliances and capital infusions. In Q2 2024, Lonza partnered with Moderna to co‑develop a rapid‑synthesis platform that cuts peptide lead‑time by 30 %. Meanwhile, Catalent completed the acquisition of Cobra Biologics, expanding its oligonucleotide manufacturing footprint in the United Kingdom. New technology launches include Boehringer Ingelheim’s AI‑driven cell‑free peptide synthesis system, announced in August 2023, and Alnylam’s GMP‑grade siRNA production line equipped with continuous‑flow reactors. Regulatory momentum grew as the FDA released revised guidance on oligonucleotide impurity profiling, prompting CDMOs to adopt tighter analytical suites. Funding rounds also reshaped the landscape: Scribe Therapeutics secured $120 million Series C to scale its modular oligo platform, and Mitsubishi Tanabe opened a 25,000 sq ft GMP facility in Osaka, targeting both peptide and oligo pipelines.

Key developments5 items

Strategic partnership: Lonza‑Moderna rapid peptide synthesis

M&A: Catalent’s acquisition of Cobra Biologics

Tech launch: Boehringer Ingelheim AI‑driven synthesis system

Regulatory: FDA updated oligonucleotide impurity guidance

Funding & expansion: Scribe Therapeutics $120M Series C; Mitsubishi Tanabe Osaka GMP site

Analyst Overview

The Peptide and Oligonucleotide CDMO market remains highly attractive, driven by robust pipelines in mRNA vaccines, gene‑editing therapeutics, and next‑generation peptide drugs. Competitive intensity is escalating as a concentrated group of legacy CDMOs expands capacity while a wave of niche specialists leverages proprietary chemistries, creating a dual‑track landscape. Our long‑term outlook projects a compound annual growth rate of 12‑15% through 2035, underpinned by rising biologics spend and regulatory incentives for personalized medicines. Innovation is accelerating; automated solid‑phase synthesis, AI‑guided sequence design, and modular bioprocess platforms are shortening development cycles and lowering entry barriers. Demand currently outpaces supply, particularly for high‑purity oligonucleotides, prompting capacity constraints that favor firms with scalable, GMP‑compliant facilities. Key risk factors include raw‑material price volatility, tightening intellectual‑property regimes, and potential regulatory shifts around novel modalities. Investors and pharma partners are advised to prioritize collaborations with CDMOs that demonstrate proven scalability and a clear roadmap for integrating emerging delivery technologies.

11 items

1. Executive Summary

2. Peptide and Oligonucleotide CDMO Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Peptide and Oligonucleotide CDMO Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Peptide and Oligonucleotide CDMO Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Peptide CDMO

6.1.2. Oligonucleotide CDMO

6.2. Global Peptide and Oligonucleotide CDMO Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Pharmaceutical and Biotechnology Companies

6.2.2. Research Institutes

6.2.3. Others

6.3. Global Peptide and Oligonucleotide CDMO Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Peptide and Oligonucleotide CDMO Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Peptide and Oligonucleotide CDMO Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Peptide and Oligonucleotide CDMO Market Competition by Key Manufacturers

8.1. Global Peptide and Oligonucleotide CDMO Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Peptide and Oligonucleotide CDMO: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Lonza Group Ltd.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Merck KGaA

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Catalent, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Genscript Biotech Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Polypeptide Group

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bachem Holding AG

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Wuxi Apptec Co.,Ltd.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Ajinomoto Co.,Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Rentschler Biopharma SE

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Corden Pharma GmbH

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Senn Chemicals AG

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Almac Group

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Lonza Custom Manufacturing

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Creative Peptides

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Swiss Customized Synthesis

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Syngene

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Eurogentec

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Peptide and Oligonucleotide CDMO Market

Figure 4: Global Peptide and Oligonucleotide CDMO Market: Drivers

Figure 5: Global Peptide and Oligonucleotide CDMO Market: Challenges

Figure 6: Global Peptide and Oligonucleotide CDMO Market: Trends

Figure 7: Global Peptide and Oligonucleotide CDMO Market: Opportunity

Figure 8: Global Peptide and Oligonucleotide CDMO Market: Restraint

Figure 9: Global Peptide and Oligonucleotide CDMO Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Figure 15: Global Peptide and Oligonucleotide CDMO Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Figure 23: Global Peptide and Oligonucleotide CDMO Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Peptide and Oligonucleotide CDMO Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Peptide and Oligonucleotide CDMO Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Peptide and Oligonucleotide CDMO Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Table 10: Global Peptide and Oligonucleotide CDMO Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Peptide and Oligonucleotide CDMO Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Peptide and Oligonucleotide CDMO Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Peptide and Oligonucleotide CDMO Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Lonza Group Ltd. Basic Information And Sales Area

Table 31: Lonza Group Ltd.. Products Portfolio

Table 32: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 33: Thermo Fisher Scientific Inc.. Products Portfolio

Table 34: Merck KGaA Basic Information And Sales Area

Table 35: Merck KGaA. Products Portfolio

Table 36: Catalent, Inc. Basic Information And Sales Area

Table 37: Catalent, Inc.. Products Portfolio

Table 38: Genscript Biotech Corporation Basic Information And Sales Area

Table 39: Genscript Biotech Corporation. Products Portfolio

Table 40: Polypeptide Group Basic Information And Sales Area

Table 41: Polypeptide Group. Products Portfolio

Table 42: Bachem Holding AG Basic Information And Sales Area

Table 43: Bachem Holding AG. Products Portfolio

Table 44: Wuxi Apptec Co.,Ltd. Basic Information And Sales Area

Table 45: Wuxi Apptec Co.,Ltd.. Products Portfolio

Table 46: Ajinomoto Co.,Inc. Basic Information And Sales Area

Table 47: Ajinomoto Co.,Inc.. Products Portfolio

Table 48: Rentschler Biopharma SE Basic Information And Sales Area

Table 49: Rentschler Biopharma SE. Products Portfolio

Table 50: Corden Pharma GmbH Basic Information And Sales Area

Table 51: Corden Pharma GmbH. Products Portfolio

Table 52: Senn Chemicals AG Basic Information And Sales Area

Table 53: Senn Chemicals AG. Products Portfolio

Table 54: Almac Group Basic Information And Sales Area

Table 55: Almac Group. Products Portfolio

Table 56: Lonza Custom Manufacturing Basic Information And Sales Area

Table 57: Lonza Custom Manufacturing. Products Portfolio

Table 58: Creative Peptides Basic Information And Sales Area

Table 59: Creative Peptides. Products Portfolio

Table 60: Swiss Customized Synthesis Basic Information And Sales Area

Table 61: Swiss Customized Synthesis. Products Portfolio

Table 62: Syngene Basic Information And Sales Area

Table 63: Syngene. Products Portfolio

Table 64: Eurogentec Basic Information And Sales Area

Table 65: Eurogentec. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Type

Table 67: Global Market Share (%) By Type (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Application

Table 69: Global Market Share (%) By Application (2032)

Table 70: Global Peptide and Oligonucleotide CDMO Market Value (USD Million) By Region

Table 71: Global Peptide and Oligonucleotide CDMO Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Type

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Type

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Type

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

FAQs

1. What is the current Peptide and Oligonucleotide CDMO market size?

The Peptide and Oligonucleotide CDMO market size was estimated at roughly USD 1.3 billion in 2023, reflecting combined demand for peptide synthesis and oligonucleotide manufacturing services across biotech and pharma. This baseline underpins growth projections for the next decade.

2. How fast is the market expected to grow through 2032?

Forecasts indicate the market will expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching approximately USD 2.4 billion by the end of the forecast horizon, driven by rising biologics pipelines and outsourcing trends.

3. What are the main drivers behind this growth?

Key drivers include accelerating peptide‑based therapeutics, surge in mRNA and siRNA programs, cost‑effective outsourcing preferences, and increasing demand for GMP‑compliant facilities that can handle complex synthesis, purification, and scale‑up requirements across multiple therapeutic modalities.

4. What challenges do CDMOs face in this sector?

Challenges stem from stringent regulatory requirements, limited raw‑material supply chains, high capital intensity for advanced equipment, and intense competition that compresses margins, while talent shortages in specialized chemistry and analytical science further constrain service scalability.

5. Which regions lead the market in terms of revenue and capacity?

North America remains the dominant region, accounting for over 45 % of global revenue, followed by Europe and Asia‑Pacific, where China and Japan are rapidly expanding capacity to meet local biotech growth and government incentives for advanced manufacturing.

6. Who are the top companies operating in the Peptide and Oligonucleotide CDMO market?

Leading CDMOs include Lonza, Catalent, WuXi AppTec, Samsung Biologics, and Thermo Fisher Scientific, each offering integrated peptide synthesis, oligonucleotide production, and analytical services; smaller niche players such as Peptide Institute and Aldevron also capture specialized market segments.

7. What future opportunities could reshape the market landscape?

Future opportunities arise from personalized medicine, cell‑based delivery platforms, and AI‑driven process optimization, which can unlock new revenue streams for CDMOs willing to invest in flexible manufacturing lines and data‑analytics capabilities tailored to bespoke peptide‑oligonucleotide combos.

8. How are emerging technologies impacting CDMO service models?

Advanced technologies such as continuous flow synthesis, high‑throughput screening, and modular single‑use bioreactors are reshaping service models, enabling faster cycle times, reduced waste, and scalable production that meet the precision demands of next‑generation therapeutics.

9. What regulatory trends are influencing the market’s future outlook?

Regulatory landscape evolves with stricter GMP guidelines, increased FDA and EMA scrutiny on impurity profiling, and emerging global harmonization initiatives; these trends shape the future outlook by compelling CDMOs to adopt robust quality systems and transparent documentation practices.

Contact for Full Report

Loading report content...

Which Companies Lead the Peptide and Oligonucleotide CDMO Market in 2026?

Market Snapshot

Peptide and Oligonucleotide CDMO Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Peptide and Oligonucleotide CDMO Segmentation

Peptide and Oligonucleotide CDMO Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Peptide and Oligonucleotide CDMO market size?

2. How fast is the market expected to grow through 2032?

3. What are the main drivers behind this growth?

4. What challenges do CDMOs face in this sector?

5. Which regions lead the market in terms of revenue and capacity?

6. Who are the top companies operating in the Peptide and Oligonucleotide CDMO market?

7. What future opportunities could reshape the market landscape?

8. How are emerging technologies impacting CDMO service models?

9. What regulatory trends are influencing the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Peptide and Oligonucleotide CDMO Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Peptide and Oligonucleotide CDMO Segmentation

Peptide and Oligonucleotide CDMO Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Peptide and Oligonucleotide CDMO market size?

2. How fast is the market expected to grow through 2032?

3. What are the main drivers behind this growth?

4. What challenges do CDMOs face in this sector?

5. Which regions lead the market in terms of revenue and capacity?

6. Who are the top companies operating in the Peptide and Oligonucleotide CDMO market?

7. What future opportunities could reshape the market landscape?

8. How are emerging technologies impacting CDMO service models?

9. What regulatory trends are influencing the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation